CO5190701A1 - Tratamiento de combinacion con ii-1ra y compuestos que inhiben el procesamiento y la liberacion de ii-1 - Google Patents

Tratamiento de combinacion con ii-1ra y compuestos que inhiben el procesamiento y la liberacion de ii-1

Info

Publication number
CO5190701A1
CO5190701A1 CO00066883A CO00066883A CO5190701A1 CO 5190701 A1 CO5190701 A1 CO 5190701A1 CO 00066883 A CO00066883 A CO 00066883A CO 00066883 A CO00066883 A CO 00066883A CO 5190701 A1 CO5190701 A1 CO 5190701A1
Authority
CO
Colombia
Prior art keywords
alkyl
aryl
heteroaryl
piperidyl
amino
Prior art date
Application number
CO00066883A
Other languages
English (en)
Spanish (es)
Inventor
Bruce Henry Littman
Louise Goodwin Woodwort Thasia
Mark Anthony Dombroski
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5190701A1 publication Critical patent/CO5190701A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CO00066883A 1999-09-14 2000-09-05 Tratamiento de combinacion con ii-1ra y compuestos que inhiben el procesamiento y la liberacion de ii-1 CO5190701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15401099P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
CO5190701A1 true CO5190701A1 (es) 2002-08-29

Family

ID=22549650

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00066883A CO5190701A1 (es) 1999-09-14 2000-09-05 Tratamiento de combinacion con ii-1ra y compuestos que inhiben el procesamiento y la liberacion de ii-1

Country Status (13)

Country Link
EP (1) EP1214087A1 (fr)
JP (1) JP2003509378A (fr)
AR (1) AR033650A1 (fr)
AU (1) AU6464400A (fr)
BR (1) BR0014003A (fr)
CA (1) CA2383026A1 (fr)
CO (1) CO5190701A1 (fr)
EC (1) ECSP003652A (fr)
GT (1) GT200000155A (fr)
PA (1) PA8502901A1 (fr)
PE (1) PE20010685A1 (fr)
TN (1) TNSN00183A1 (fr)
WO (1) WO2001019390A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7619066B2 (en) 2004-04-02 2009-11-17 Amgen Inc. IL-1ra variants
WO2008129288A2 (fr) * 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides utiles dans le traitement de l'inflammation
EP3578547B1 (fr) * 2015-02-16 2021-05-26 The University of Queensland Sulfonylurées, composés apparentés, et leur utilisation
SG11201806745RA (en) 2016-02-16 2018-09-27 Univ Queensland Sulfonylureas and related compounds and use of same
WO2017184624A1 (fr) 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Composés et compositions pour traiter des états associés à une activité de nlrp
CA3047336A1 (fr) 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Composes chimiques comme inhibiteurs de l'activite interleukine-1
AU2017416068A1 (en) 2017-05-24 2019-10-31 The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Novel compounds and uses
EP3634951A1 (fr) 2017-06-09 2020-04-15 Cadila Healthcare Limited Nouveaux composés de sulfoximine substitués
EP3649112A1 (fr) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylurées et sulfonylthiourées en tant qu'inhibiteurs de nlrp3
WO2019008025A1 (fr) 2017-07-07 2019-01-10 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
US11203579B2 (en) 2017-07-24 2021-12-21 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
EP3668840A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
WO2019034693A1 (fr) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3
JP2020531453A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア
MX2020001778A (es) 2017-08-15 2020-03-24 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida.
WO2019043610A1 (fr) 2017-08-31 2019-03-07 Cadila Healthcare Limited Nouveaux dérivés de sulfonylurées substitués
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
WO2019166619A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
US11530200B2 (en) 2018-03-02 2022-12-20 Inflazome Limited Compounds
WO2020010143A1 (fr) 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Modulateurs de nlrp
PE20211049A1 (es) 2018-07-20 2021-06-04 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1
EP3870565A1 (fr) 2018-10-24 2021-09-01 Novartis AG Composés et compositions pour traiter des états associés à l'activité des nlrp
EP3911631A4 (fr) 2019-01-14 2022-09-28 Cadila Healthcare Limited Nouveaux dérivés de sulfonylurées substitués
KR20230015418A (ko) * 2020-05-25 2023-01-31 베이징 브이디제이바이오 컴퍼니 리미티드 인터루킨-1 수용체 길항제 및 이를 포함하는 융합 단백질

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
WO1998032733A1 (fr) * 1997-01-29 1998-07-30 Pfizer Inc. Derives de sulfonyluree et leur application en matiere de regulation de l'activite de l'interleukine-1
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
EP0987552A3 (fr) * 1998-08-31 2000-06-07 Pfizer Products Inc. Protéines de liaison pour diarylsulfonylurée

Also Published As

Publication number Publication date
PE20010685A1 (es) 2001-07-03
JP2003509378A (ja) 2003-03-11
EP1214087A1 (fr) 2002-06-19
AU6464400A (en) 2001-04-17
TNSN00183A1 (fr) 2005-11-10
WO2001019390A1 (fr) 2001-03-22
AR033650A1 (es) 2004-01-07
PA8502901A1 (es) 2002-02-21
CA2383026A1 (fr) 2001-03-22
BR0014003A (pt) 2002-05-21
ECSP003652A (es) 2002-04-23
GT200000155A (es) 2002-03-08

Similar Documents

Publication Publication Date Title
CO5190701A1 (es) Tratamiento de combinacion con ii-1ra y compuestos que inhiben el procesamiento y la liberacion de ii-1
AR036042A1 (es) Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
NO20023043D0 (no) Substituerte oksazolidinoner og deres anvendelse innenfor feltet blodkoagulasjon
NO20060973L (no) Pyridylderivater og deres anvendelse som tempeutiske midler
HUP0105414A2 (hu) Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
BR0108118A (pt) Inibidores da catepsina k de dipeptìdeo nitrila
CO5150226A1 (es) Amidas de aminoacidos modificadas, medicamentos que contienen estos compuestos y procedimiento para su preparacion
TNSN06036A1 (en) Pyridyl derivatives and their use as therapeutic agents
TW200624427A (en) Heterocyclic derivatives and their use as therapeutic agents
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
ECSP066313A (es) Derivados de la piridazina y su uso como agentes terapéuticos
ES2328820T3 (es) Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
BR0015193A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
WO2006034440A3 (fr) Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
SE9903760D0 (sv) New compounds
MX2007003321A (es) Derivados heterociclicos y su uso como agentes terapeuticos.
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
DOP2002000456A (es) Inhibidores de la alquin-aril fosfodiesterasa-4''
UY28132A1 (es) Derivados de pirrolopirimidina
CO5251399A1 (es) Derivados de purina
CO5080747A1 (es) Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p
AR034203A1 (es) Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento
AR036248A1 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
KR890017248A (ko) 종양억제제인 방향족 및 헤테로사이클릭 카복스아미드 유도체
CO5261519A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos

Legal Events

Date Code Title Description
FC Application refused